Comparing what was on the NKF site before and after.  Previously this is what they had for Apabetalone:  

Apabetalone reduces Cardiovascular Events in Patients with Chronic Kidney Disease, Type 2 Diabetes, and Recent Acute Coronary Syndrome: A BETonMACE trial report

The speaker was listed as Kamyar Kalantar-Zadeh.  

Now it appears that its been redacted to this:  "- Review clinical trial data of a novel treatment strategy to improve cardiovascular disease in patients with diabetic kidney disease" with no speaker listed.